HIMS Stock Slides After Earnings as GLP-1 Risk Spooks Investors Skip to Main Content

HIMS Stock Slides as GLP-1 Regulatory Risk Takes Center Stage

|
Share on social media

Hims & Hers Health (HIMS) stock is sliding in Tuesday’s session following a mixed Q4 earnings report released after the close on Feb. 23. While the company beat EPS estimates handily ($0.08 vs. $0.03 expected), revenue of $617.8M came in slightly below the $619.2M consensus, and Q1 guidance of $600M–$625M badly trailed the $653M analyst estimate. Adding to the pressure, management disclosed meaningful uncertainty around the FDA, HHS, and DOJ’s potential actions on the marketing of compounded GLP-1 products, a core pillar of the company’s growth narrative.

hims stock logo

Key Drivers of the HIMS Stock Move

  • Main Catalyst: Q4 revenue miss combined with below-consensus Q1 guidance and a warning about regulatory risk on compounded GLP-1 products rattled investors. Management also flagged headwinds from its Super Bowl ad spend and shifts in shipping cadences.
  • Bull Case: Subscribers crossed 2.5 million, demonstrating continued platform growth. Full-year 2026 sales guidance of $2.7B–$2.9B brackets the $2.741B consensus, and the EPS beat of 167% shows improving profitability. The $1.15B acquisition of Eucalyptus signals aggressive international expansion into Australia, Japan, the UK, Germany, and Canada.
  • Bear Case: The GLP-1 regulatory cloud is the dominant risk. If the FDA, HHS, or DOJ moves to restrict compounded semaglutide marketing, a significant growth engine could stall. Q1 guidance of up to $653M is tracking well below Street expectations, and the company remains on the Top 10 Most Shorted Stocks list.
HIMS stock graph

The setup heading into this earnings reaction is challenging. HIMS entered the print already under sector pressure, with relative performance deteriorating steadily since late 2025. The regulatory language around compounded GLP-1s is the single biggest wildcard: uncertainty here is not priced in with precision, which means the stock could face additional volatility in either direction depending on any FDA communication. Short interest remains elevated, which creates both squeeze potential and downside amplification risk.

HIMS Smart Money Activity

Insider filings show routine stock appreciation right disposals by CFO Oluyemi Okupe earlier in the quarter, totaling roughly $720K. No unusual selling clusters or congressional trades were detected. Institutional positioning remains mixed as investors digest regulatory developments tied to GLP-1 exposure.

HIMS smart money table

HIMS Unusual Options

Options flow turned decidedly mixed following the Eucalyptus announcement and weak guidance. Heavy bullish sweeps hit March $14-$16 calls on February 20, with over $600K in premium paid across multiple strikes. However, substantial bearish positioning emerged in longer-dated contracts, including a $859K purchase of May $55 puts and $343K in June $32 puts on February 20. Post-earnings on February 23, traders deployed synthetic strategies with simultaneous call and put purchases on January 2027 $5 strikes totaling over $1M, suggesting volatility plays rather than directional bets.

HIMS unusual options chart

HIMS Analyst Focus

Analyst sentiment deteriorated sharply in February. BTIG maintained its buy rating but slashed the price target 29% from $85 to $60 on February 2. Bank of America cut to $21 (February 9) and Citigroup to $16.5 (February 9), both reiterating sell ratings. TD Cowen reduced its hold target from $30 to $20. Evercore initiated coverage with a neutral $33 target in mid-January before the sell-off intensified. The median 2026 price target across recent ratings sits near $26, implying 68% upside from current levels but reflecting deep skepticism about near-term catalysts.

HIMS analyst table

HIMS Seasonality

Based on data since October 2019 (6-7 samples per month), HIMS shows strongest seasonal performance in November (71% positive, +18.9% average) and weakest in August (33% positive, -14.6% average) and October (33% positive, -8.7% average). February historically posts a 71% win rate with +7.1% average gains, though March turns negative (33% positive, -6.2% average). The current February weakness contradicts historical patterns, suggesting fundamental rather than seasonal pressures.

HIMS seasonality chart

HIMS Relative Performance

HIMS has sharply underperformed healthcare peers in recent weeks following the FDA announcement. After being one of the digital health sector’s breakout winners in 2024, the stock has fallen into the lower decile of relative strength versus sector comparables. The rapid shift from momentum leader to regulatory risk story highlights institutional de-risking tied specifically to compounded GLP-1 exposure rather than broad sector weakness.

Stay up-to-date: Subscribe to posts like this!

Receive automated updates from the Posts category
This site is protected by reCAPTCHA and the Google Privacy Policy and Google Terms of Service apply. Don't worry, we hate spam, too! See TrendSpider Privacy Policy for details.

Latest posts

|

JPMorgan Chase Software Bug Hits Consumer Banking: What Traders Need to Know About JPM Stock

JPMorgan Chase & Co. (JPM) stock confirmed a temporary software bug is disrupting consumer banking operations, with Chase, Bank of America, and Wells Fargo customers all reporting widespread online banking outages on November 16, 2026. A Zelle representative specifically stated the technical issue “originated with Chase.” JPM shares have shown resilience despite the headlines, underpinned […]
|

Jensen Huang Resigns as NVIDIA CEO: What it Means for NVDA Stock

After 33 years at the helm of the company he co-founded, Jensen Huang resigned as President, CEO, and board member of NVDA effective immediately on November 12, 2026. The departure was triggered by a deepening scandal involving alleged ties to a suspected Chinese intelligence asset, a second workplace affair, and a cascade of regulatory and […]
|

CoreWeave Stock Q3 Earnings: $3.7B Revenue Beat & 2026 Guide Raise

CoreWeave (CRWV) stock delivered a commanding Q3 2026 earnings beat on November 10, posting revenue of $3.7 billion against a consensus estimate of $3.5 billion and an adjusted EPS loss of $0.95 versus the expected $1.53 — a 38% EPS beat. The company simultaneously raised its full-year 2026 revenue guidance to $13.0–$13.3 billion, sparking an […]
|

Hims & Hers Stock Slides as Q3 EPS Miss & Weak Guide Shadow 49% Sales

Hims & Hers Health (HIMS) stock delivered another quarter of robust top-line expansion in Q3 2026, with revenue surging 48.7% year-over-year to $890.4M. However, an adjusted EPS miss and a materially below-consensus Q4 outlook sent shares sharply lower after the report, reflecting growing investor concern about profitability and the post-GLP-1 compounding transition. Key Takeaways: Beat […]